Company Profile
Sensible Biotherapeutics
Sensible Biotherapeutics is a family-owned pharmaceutical startup company headquartered in the historic city of Buffalo, New York. Led by Neurologist and Nuclear Medicine physician Dr. Michael A. Meyer, the company focuses on the development of pharmaceutical remedies using antisense therapy techniques. The company currently is developing potential antiviral compounds with a focus on COVID-19.
In addition to COVID-19 research, the company has been in development of a potential antiviral solution for the West Nile Virus. The company also boasts a radiopharmaceutical division that has discovered potential solutions for synthesizing fluorine-18 without a cyclotron.
Michael A. Meyer, MD
Dr. Meyer is the founder and director of Sensible Biotherapeutics, LLC. As a Mayo Clinic trained board certified Neurologist, he participated in work that led to the development of tPA as an FDA approved pharmaceutical for the treatment of acute stroke.
Prior to starting medical school, Dr Meyer was part of the original research team at Brookhaven National lab that developed PET imaging as a clinical tool, and did some of the early autoradiographic work that established the use of 18F-FDG PET imaging in Oncology.
Dr. Meyer is a University of Michigan trained board certified Nuclear Medicine physician at Invision Health in Buffalo, NY, where he also maintains a practice as a Clinical Neurologist.
Dr. Meyer is the author of Neurologic Disease, a first of its kind textbook for neurological problem solving.
Looking for the Sensible Biotherapeutics newsroom? Please click here.